Avandia Should Stay On Market With Warnings, Committee Says
Executive Summary
FDA's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees are calling for strengthened warnings for GlaxoSmithKline's type 2 diabetes drug Avandia due to cardiovascular safety concerns, but not its withdrawal from the market
You may also be interested in...
Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure
Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure
Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
Is Faster Better? Senators Question Surrogate Endpoints, Fast Track Status
Several U.S. senators are using congressional inquiry mechanisms to challenge the fundamental underpinnings of rapid FDA drug review